Short answer
Lantheus Holdings, Inc. (LNTH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
Lantheus Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Full operating results, financial figures, and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $389.9M, up 1.5%, with Neuraceq up 123.0% and PYLARIFY down 0.7%
- Adjusted EPS $1.68, up 32.3%, while GAAP EPS fell to $0.33 from $0.41
- FDA approvals for TAUKLARIFY and BRAVNETSA expand Lantheus’ neurology and radiotherapeutics opportunities
- Curium merger offers $102.50 per share cash plus CVRs worth up to $12.00 per share
- Full-year 2026 guidance suspended pending the approximately $8.0B merger; antitrust approvals remain a closing condition
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lantheus Holdings, Inc. 8-K filings
Get the next LNTH 8-K as it lands
Follow LNTH for push alerts, or ask the research agent what this filing means.